Assertio (ASRT) Competitors

Assertio (NASDAQ:ASRT) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and community ranking.

Which has stronger earnings & valuation, ASRT or RNAC?

Cartesian Therapeutics has lower revenue, but higher earnings than Assertio. Assertio is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$119.00M	0.56	-$331.94M	-$0.32	-2.19
Cartesian Therapeutics	$34.17M	7.63	-$219.71M	-$52.83	-0.19

Do analysts prefer ASRT or RNAC?

Assertio currently has a consensus target price of $2.75, suggesting a potential upside of 292.86%. Cartesian Therapeutics has a consensus target price of $42.50, suggesting a potential upside of 322.89%. Given Cartesian Therapeutics' higher probable upside, analysts clearly believe Cartesian Therapeutics is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cartesian Therapeutics	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Is ASRT or RNAC more profitable?

Assertio has a net margin of -54.46% compared to Cartesian Therapeutics' net margin of -510.72%. Assertio's return on equity of 3.79% beat Cartesian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-54.46%	3.79%	1.81%
Cartesian Therapeutics	-510.72%	N/A	-6.03%

Which has more volatility & risk, ASRT or RNAC?

Assertio has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Do insiders and institutionals hold more shares of ASRT or RNAC?

49.0% of Assertio shares are held by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are held by institutional investors. 4.0% of Assertio shares are held by company insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the MarketBeat Community favor ASRT or RNAC?

Assertio received 75 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 95.12% of users gave Cartesian Therapeutics an outperform vote while only 60.00% of users gave Assertio an outperform vote.

Company	Underperform	Outperform
Assertio	Outperform Votes 114 60.00%	Underperform Votes 76 40.00%
Cartesian Therapeutics	Outperform Votes 39 95.12%	Underperform Votes 2 4.88%

Does the media prefer ASRT or RNAC?

In the previous week, Cartesian Therapeutics had 3 more articles in the media than Assertio. MarketBeat recorded 9 mentions for Cartesian Therapeutics and 6 mentions for Assertio. Cartesian Therapeutics' average media sentiment score of 0.33 beat Assertio's score of 0.11 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cartesian Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Cartesian Therapeutics beats Assertio on 11 of the 18 factors compared between the two stocks.